Sign In
Buy AGEN
$7.00
+0.0400 (+0.575%)
At Close: Aug 10, 2026
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
06:46pm, Friday, 07'th Aug 2026
Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $1 per share a year ago.
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
07:30am, Thursday, 06'th Aug 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and p
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
04:30pm, Tuesday, 28'th Jul 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results befor
Do Options Traders Know Something About Agenus Stock We Don't?
02:16pm, Thursday, 23'rd Jul 2026
Investors need to pay close attention to AGEN stock based on the movements in the options market lately.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials e
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
01:01pm, Tuesday, 14'th Jul 2026
Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
09:16am, Tuesday, 14'th Jul 2026
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
03:10pm, Monday, 13'th Jul 2026
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
Agenus shares surge as company secures up to $340M to advance colon cancer trial
01:11pm, Monday, 13'th Jul 2026
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its b
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
10:28am, Monday, 13'th Jul 2026
Agenus Inc. (NASDAQ:AGEN) stock surged over 100% in intraday trading on Monday after the immuno-oncology company unveiled an $85 million private placement that could grow to $340 million if investors
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
10:02am, Monday, 13'th Jul 2026
Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk
Agenus shares surge as company secures up to $340M to advance colon cancer trial
08:53am, Monday, 13'th Jul 2026
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to...
VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy
07:00am, Monday, 13'th Jul 2026
VivoPower PLC (NASDAQ:VIVO, FRA:51J)’s pivot toward acquiring and developing power-secured land and powered-shell data center infrastructure has earned it...
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a pri
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01
